{"slug":"ozempic-vs-victoza)","title":"Ozempic vs Victoza","url":"https://www.aversusb.net/compare/ozempic-vs-victoza)","faqCount":5,"faqs":[{"question":"Which medication causes more weight loss?","answer":"Ozempic produces substantially more weight loss, with clinical trials (SUSTAIN-6) showing 15% average body weight reduction compared to Victoza's 5-6% reduction. This difference is significant enough that many endocrinologists now prefer Ozempic as first-line therapy for patients whose primary goal includes weight management alongside diabetes control."},{"question":"Is Ozempic better for your heart?","answer":"Yes, Ozempic shows superior cardiovascular benefits with a 26% reduction in major adverse cardiovascular events in the SUSTAIN-6 trial versus Victoza's 13% reduction in the LEADER trial. Both are GLP-1 agonists with cardiovascular benefits, but Ozempic's longer-acting formulation and higher dose potential contribute to more robust outcomes."},{"question":"Why would someone still choose Victoza over Ozempic?","answer":"Victoza remains appropriate for patients who: (1) have established tolerance to the medication with 16 years of clinical data, (2) face insurance barriers or cost concerns (typically $300-400 cheaper per month), (3) prefer a more gradual/conservative approach as a first GLP-1 therapy, or (4) have difficulty tolerating once-weekly dosing schedules. However, most new patients now initiate Ozempic due to superior efficacy."},{"question":"Can you switch from Victoza to Ozempic?","answer":"Yes, switching is common and typically straightforward. Since both are GLP-1 receptor agonists, the mechanism of action is identical. Your doctor will discontinue Victoza and start Ozempic at the appropriate dose (usually 0.25-0.5 mg weekly), gradually titrating up. Gastrointestinal side effects may temporarily increase during the transition as Ozempic is more potent."},{"question":"Are there serious side effects shared by both medications?","answer":"Both carry black box warnings for potential C-cell thyroid tumors (based on rodent studies) and pancreatitis risk. Both cause gastrointestinal side effects (nausea, vomiting, constipation, diarrhea) in 20-40% of users during the titration phase. Neither should be used if you have a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2."}],"faqPageSchema":{"@context":"https://schema.org","@type":"FAQPage","@id":"https://www.aversusb.net/compare/ozempic-vs-victoza)#faq","url":"https://www.aversusb.net/compare/ozempic-vs-victoza)","inLanguage":"en","name":"Ozempic vs Victoza — FAQ","description":"Frequently asked questions about Ozempic vs Victoza","author":{"@type":"Organization","@id":"https://www.aversusb.net/#organization","name":"A Versus B"},"isPartOf":{"@type":"Article","@id":"https://www.aversusb.net/compare/ozempic-vs-victoza)#article"},"mainEntity":[{"@type":"Question","name":"Which medication causes more weight loss?","acceptedAnswer":{"@type":"Answer","text":"Ozempic produces substantially more weight loss, with clinical trials (SUSTAIN-6) showing 15% average body weight reduction compared to Victoza's 5-6% reduction. This difference is significant enough that many endocrinologists now prefer Ozempic as first-line therapy for patients whose primary goal includes weight management alongside diabetes control.","url":"https://www.aversusb.net/compare/ozempic-vs-victoza)"}},{"@type":"Question","name":"Is Ozempic better for your heart?","acceptedAnswer":{"@type":"Answer","text":"Yes, Ozempic shows superior cardiovascular benefits with a 26% reduction in major adverse cardiovascular events in the SUSTAIN-6 trial versus Victoza's 13% reduction in the LEADER trial. Both are GLP-1 agonists with cardiovascular benefits, but Ozempic's longer-acting formulation and higher dose potential contribute to more robust outcomes.","url":"https://www.aversusb.net/compare/ozempic-vs-victoza)"}},{"@type":"Question","name":"Why would someone still choose Victoza over Ozempic?","acceptedAnswer":{"@type":"Answer","text":"Victoza remains appropriate for patients who: (1) have established tolerance to the medication with 16 years of clinical data, (2) face insurance barriers or cost concerns (typically $300-400 cheaper per month), (3) prefer a more gradual/conservative approach as a first GLP-1 therapy, or (4) have difficulty tolerating once-weekly dosing schedules. However, most new patients now initiate Ozempic due to superior efficacy.","url":"https://www.aversusb.net/compare/ozempic-vs-victoza)"}},{"@type":"Question","name":"Can you switch from Victoza to Ozempic?","acceptedAnswer":{"@type":"Answer","text":"Yes, switching is common and typically straightforward. Since both are GLP-1 receptor agonists, the mechanism of action is identical. Your doctor will discontinue Victoza and start Ozempic at the appropriate dose (usually 0.25-0.5 mg weekly), gradually titrating up. Gastrointestinal side effects may temporarily increase during the transition as Ozempic is more potent.","url":"https://www.aversusb.net/compare/ozempic-vs-victoza)"}},{"@type":"Question","name":"Are there serious side effects shared by both medications?","acceptedAnswer":{"@type":"Answer","text":"Both carry black box warnings for potential C-cell thyroid tumors (based on rodent studies) and pancreatitis risk. Both cause gastrointestinal side effects (nausea, vomiting, constipation, diarrhea) in 20-40% of users during the titration phase. Neither should be used if you have a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2.","url":"https://www.aversusb.net/compare/ozempic-vs-victoza)"}}]}}